Cerapedics recently closed a $9 million venture debt financing from GE Capital, Healthcare Financial Services.
The loan will support general business operations for Cerapedics, including the advancement of the company's United States regulatory process. Cerapedics also recently announced the preliminary outcomes data from the FDA investigational device exemption clinical trial for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion procedures.
The preliminary results indicted the i-FACTOR bone graft met pre-specified primary end points.
More Articles on Orthopedic Devices:
ConforMIS iTotal Knee Shows Promising Clinical Study Results
Ortho Development Gets FDA Clearance for Ovation Tribute Hip Stem
DePuy Synthes Power Tools Launches Anspach EG1 High Speed Electric System